Cipla and Chia Tai Tianqing Pharmaceutical Group (CTTQ), a subsidiary of Sino Biopharmaceutical (SBP Group), have entered into an exclusive license and supply agreement for rolditamig deuderuxtecan, also known as TQB2102, a potential best-in-class HER2 bispecific antibody-drug conjugate (ADC).
Under this agreement, Cipla will receive exclusive rights to develop and commercialise TQB2102 in India, South Africa and five other emerging markets. Cipla will be responsible for local clinical development, regulatory activities, and commercialisation in the licensed territories, while CTTQ will continue to manufacture and supply TQB2102.
TQB2102 is being evaluated across HER2-expressing cancers and has demonstrated encouraging clinical potential in HER2-low advanced breast cancer.
The collaboration combines SBP Group’s differentiated late-stage oncology asset and development and manufacturing capabilities with Cipla’s established regulatory, medical, market access and commercial presence across India, South Africa and other emerging markets.
The partnership is expected to accelerate local development and regulatory approvals, enabling patient access across licensed countries, subject to applicable approvals.
Achin Gupta, managing director and global chief executive officer at Cipla, said, “Breast cancer remains a significant healthcare challenge, and this agreement strengthens our oncology portfolio with a promising HER2-targeted antibody-drug conjugate. Through our partnership with SBP Group and CTTQ, we aim to accelerate development and, subject to regulatory approvals, expand access to this innovative treatment across licensed territories.”
Eric Tse, CEO, SBP Group, said TQB2102 has shown encouraging clinical potential across different HER2-expressing breast cancer populations.
“Cipla’s scale, local expertise and commitment to patient access make it a strong partner to help bring this treatment to patients across India, South Africa and other emerging markets,” he added.
